Ed Mathers is a General Partner at NEA; he joined the firm as a Partner in August 2008 and is focused on biotechnology and specialty pharmaceuticals investments. He is a director of Rhythm Pharmaceuticals (NASDAQ: RYTM), Synlogic (NASDAQ:SYBX), Trevi Therapeutics (NASDAQ: TRVI), Mirum Pharmaceuticals (NASDAQ:MIRM), and ObsEva (NASDAQ:OBSV), as well as a number of private life sciences companies. Prior to joining NEA, Mr. Mathers served as executive vice president, corporate development and venture at MedImmune, a biopharmaceutical company, and led its venture capital subsidiary, MedImmune Ventures. Prior to this, he spent 15 years at Glaxo Wellcome (GlaxoSmithKline), where he held sales and marketing positions of increasing responsibility. Mr. Mathers earned his bachelor’s degree in chemistry from North Carolina State University.